

Engagement Report for Clinical Commissioning Policies

Unique Reference Number	A13X05
Policy Title	Rituximab for the treatment of dermatomyositis and polymyositis (Adults)
Accountable Commissioner	Jon Gulliver
Clinical Reference Group	Specialised Rheumatology
Which stakeholders were contacted to be involved in policy development?	Specialised Rheumatology CRG membership Specialised Rheumatology CRG registered stakeholders Rare Diseases Advisory Group (RDAG)
Identify the relevant Royal College or Professional Society to the policy and indicate how they have been involved	Representatives of relevant Royal College or Professional Societies were contacted for Stakeholder Testing as part of the CRG
Which stakeholders have actually been involved?	All of the key stakeholders listed above were invited to comment
Explain reason if there is any difference from previous question	Not applicable

FOR PUBLIC CONSULTATION ONLY

<p>Identify any particular stakeholder organisations that may be key to the policy development that you have approached that have yet to be engaged. Indicate why?</p>	<p>None</p>
<p>How have the stakeholders been involved? What engagement methods have been used?</p>	<p>The draft policy was circulated to the full membership of the CRG and registered stakeholders for two weeks for their views, both to establish whether any amendments to the policy are required, and to understand from their perspective what the key questions to ask at consultation might be.</p> <p>Four responses were received: two from CRG members (one from a CRG sector representative and one from an individual CRG member) and two from CRG-registered stakeholders (both individual responses).</p> <p>Key response themes were as follows:</p> <ul style="list-style-type: none"> (1) Respondents requested for clarification on the use of IVIg. PWG noted that this policy proposition should not preclude use of IVIg as outlined within the existing DOH guidelines (2) A CRG member suggested some minor edits on section 7 proposed criteria for commissioning to clarify the outcome measures (3) A CRG member requested an edit on section 11 proposed audit requirements (4) Additional stakeholders (BSR) were identified to include in the consultation
<p>What has happened or changed as a result of their input?</p>	<p>Stakeholders were invited to comment. Minor changes were made to the policy proposition. No change was made to the evidence review. Additional stakeholders identified will be invited to comment as part of the public consultation.</p>
<p>How are stakeholders being kept informed of progress with policy development as a result of their input?</p>	<p>This engagement report, along with the updated policy proposition will be circulated as part of the public consultation. Stakeholders will be notified and invited to comment further</p>
<p>What level of wider public consultation is recommended by the CRG for the NPOC Board to agree as a result of stakeholder involvement?</p>	<p>Public consultation for a period of 30 days as supported by stakeholders</p>